UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

Annals of oncology, 2017-05, Vol.28 (5), p.1036-1041

2017

Volltextzugriff (PDF)

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

British journal of cancer, 2010-08, Vol.103 (4), p.469-474

2010

Volltextzugriff (PDF)

500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028

European journal of cancer (1990), 2015-09, Vol.51, p.S102-S102

2015

Volltextzugriff (PDF)

525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028

European journal of cancer (1990), 2015-09, Vol.51, p.S112-S112

2015

Volltextzugriff (PDF)

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

The New England journal of medicine, 2015-06, Vol.372 (26), p.2509-2520

2015

Volltextzugriff (PDF)

502 Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028

European journal of cancer (1990), 2015-09, Vol.51, p.S103-S103

2015

Volltextzugriff (PDF)

Apoptosis of colorectal adenocarcinoma (COLO 201) by tumour necrosis factor‐alpha (TNF‐α) and/or interferon‐gamma (IFN‐γ), resulting from down‐modulation of Bcl‐2 expression

Clinical and experimental immunology, 1998-01, Vol.111 (1), p.211-218

1998

Volltextzugriff (PDF)

P-342 Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction or gastric cancer

Annals of oncology, 2020-07, Vol.31, p.S201

2020

Volltextzugriff (PDF)

HIF-1α induces cell cycle arrest by functionally counteracting Myc

The EMBO journal, 2004-05, Vol.23 (9), p.1949-1956

2004

Volltextzugriff (PDF)

HIF-1α Induces Genetic Instability by Transcriptionally Downregulating MutSα Expression

Molecular cell, 2005-03, Vol.17 (6), p.793-803

2005

Volltextzugriff (PDF)

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

The lancet oncology, 2016-06, Vol.17 (6), p.717-726

2016

Volltextzugriff (PDF)

P-138 Margetuximab combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction or gastric cancer

Annals of oncology, 2021-07, Vol.32, p.S146

2021

Volltextzugriff (PDF)

231TiP KEYNOTE-059: Phase 2 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma

Annals of oncology, 2015-12, Vol.26, p.ix42-ix42

2015

Volltextzugriff (PDF)

232TiP KEYNOTE-061: Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma

Annals of oncology, 2015-12, Vol.26, p.ix42-ix42

2015

Volltextzugriff (PDF)

KEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer

Annals of oncology, 2017-09, Vol.28, p.v616-v617

2017

Volltextzugriff (PDF)

P-105 Pembrolizumab (MK-3475) for patients with recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: The phase 2 KEYNOTE-059 study

Annals of oncology, 2015-06, Vol.26, p.iv29

2015

Volltextzugriff (PDF)

P-106 Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Randomized, open-label, phase 3 KEYNOTE-061 study

Annals of oncology, 2015-06, Vol.26, p.iv29

2015

Volltextzugriff (PDF)

Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells

Journal of ethnopharmacology, 1999-08, Vol.66 (2), p.227-233

1999

Volltextzugriff (PDF)

Tumor suppressor p53 represses transcription of RECQ4 helicase

Oncogene, 2005-03, Vol.24 (10), p.1738-1748

2005

Volltextzugriff (PDF)

LBA-04 Clinical outcomes and their correlation with gene expression in patients with advanced gastric cancer treated with pembrolizumab (MK-3475): KEYNOTE-012

Annals of oncology, 2015-06, Vol.26, p.iv118

2015

Volltextzugriff (PDF)

Flux growth of thulium vanadate single crystals

Journal of crystal growth, 1999-03, Vol.198, p.449-453

1999

Volltextzugriff (PDF)

Correlation of N-myc downstream-regulated gene 1 expression with clinical outcomes of colorectal cancer patients of different race/ethnicity

World journal of gastroenterology : WJG, 2007-05, Vol.13 (20), p.2803

2007

Volltextzugriff (PDF)

Controlling Air Leaks Using Free Pericardial Fat Pads as Surgical Sealant in Pulmonary Resection

The Annals of thoracic surgery, 2015-04, Vol.99 (4), p.1170-1175

2015

Volltextzugriff (PDF)

Treatment of anomalous arterial supply to the basal segment of left lung with aortic stent graft

Journal of vascular surgery cases and innovative techniques, 2022-09, Vol.8 (3), p.350-352

2022

Volltextzugriff (PDF)

1 – 25 von 128

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(96)
Mit Volltextzugriff
(110)

Publikationsform

Sprache

Englisch
(116)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028

525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

502 Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028

Apoptosis of colorectal adenocarcinoma (COLO 201) by tumour necrosis factor‐alpha (TNF‐α) and/or interferon‐gamma (IFN‐γ), resulting from down‐modulation of Bcl‐2 expression

P-342 Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction or gastric cancer

HIF-1α induces cell cycle arrest by functionally counteracting Myc

HIF-1α Induces Genetic Instability by Transcriptionally Downregulating MutSα Expression

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

P-138 Margetuximab combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction or gastric cancer

231TiP KEYNOTE-059: Phase 2 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma

232TiP KEYNOTE-061: Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

KEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer

P-105 Pembrolizumab (MK-3475) for patients with recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: The phase 2 KEYNOTE-059 study

P-106 Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Randomized, open-label, phase 3 KEYNOTE-061 study

Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells

Tumor suppressor p53 represses transcription of RECQ4 helicase

LBA-04 Clinical outcomes and their correlation with gene expression in patients with advanced gastric cancer treated with pembrolizumab (MK-3475): KEYNOTE-012

Flux growth of thulium vanadate single crystals

Correlation of N-myc downstream-regulated gene 1 expression with clinical outcomes of colorectal cancer patients of different race/ethnicity

Controlling Air Leaks Using Free Pericardial Fat Pads as Surgical Sealant in Pulmonary Resection

Treatment of anomalous arterial supply to the basal segment of left lung with aortic stent graft

Suchergebnisse filtern